MERCK & COMPANY INC

NYSE: MRK (Merck & Company, Inc.)

Last update: 2 days ago, 5:01PM

101.03

-0.80 (-0.79%)

  • 1D -0.79%
  • 5D 0.63%
  • 1M 20.47%
  • 6M 29.08%
  • YTD 1.88%
  • 1Y -0.34%
  • 5Y 29.22%
Previous Close 101.83
Open 101.53
Volume 9,098,392
Avg. Volume (3M) 13,157,874
Market Cap 252,351,037,440
Price / Earnings (TTM) 13.36
Price / Earnings (Forward) 10.11
Price / Sales 3.73
Price / Book 4.55
52 Weeks Range
73.31 (-27%) — 105.84 (4%)
Earnings Date 30 Oct 2025
TTM Dividend Yield 1.60%
Profit Margin 27.27%
Operating Margin (TTM) 40.06%
Diluted EPS (TTM) 6.88
Quarterly Revenue Growth (YOY) -1.60%
Quarterly Earnings Growth (YOY) 6.70%
Total Debt/Equity (MRQ) 71.99%
Current Ratio (MRQ) 1.41
Operating Cash Flow (TTM) 20.88 B
Levered Free Cash Flow (TTM) 17.12 B
Return on Assets (TTM) 13.81%
Return on Equity (TTM) 39.29%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Bearish
Drug Manufacturers - General (Global) Bullish Bearish
Stock Merck & Company, Inc. Bullish Bearish

AIStockmoo Score

0.3
Analyst Consensus -1.5
Insider Activity NA
Price Volatility -0.5
Technical Moving Averages -1.0
Technical Oscillators 4.0
Average 0.25

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
MRK 252 B 1.60% 13.36 4.55
JNJ 488 B 0.61% 19.57 6.20
ABBV 402 B 1.44% 172.39 50.46
PFE 146 B 1.68% 14.92 1.55
BMY 100 B 1.26% 16.52 5.40
GSK 97 B 0.81% 13.71 4.52

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.06%
% Held by Institutions 80.62%
52 Weeks Range
73.31 (-27%) — 105.84 (4%)
Price Target Range
90.00 (-10%) — 125.00 (23%)
High 125.00 (Wells Fargo, 23.73%) Buy
Median 105.50 (4.42%)
Low 90.00 (Berenberg, -10.92%) Hold
Average 106.83 (5.74%)
Total 2 Buy, 4 Hold
Avg. Price @ Call 91.20
Firm Date Target Price Call Price @ Call
Goldman Sachs 02 Dec 2025 120.00 (18.78%) Buy 101.03
Wells Fargo 24 Nov 2025 125.00 (23.73%) Buy 100.40
Deutsche Bank 18 Nov 2025 111.00 (9.87%) Hold 96.43
Morgan Stanley 03 Nov 2025 100.00 (-1.02%) Hold 82.49
Citigroup 13 Oct 2025 95.00 (-5.97%) Hold 85.70
Berenberg 17 Sep 2025 90.00 (-10.92%) Hold 81.14

No data within this time range.

  • 3M
Date Type Details
04 Dec 2025 CNBC RFK Jr.'s vaccine panel to vote on changing hepatitis B shot recommendation for babies
01 Dec 2025 Announcement Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
26 Nov 2025 Announcement Merck to Participate in the Citi 2025 Global Healthcare Conference
26 Nov 2025 Announcement Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
24 Nov 2025 Announcement Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
21 Nov 2025 Announcement Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
21 Nov 2025 Announcement FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
19 Nov 2025 Announcement Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
19 Nov 2025 Announcement European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
18 Nov 2025 Announcement Merck Announces First-Quarter 2026 Dividend
18 Nov 2025 Announcement Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
14 Nov 2025 Announcement Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
13 Nov 2025 Announcement Merck to Participate in the Jefferies Global Healthcare Conference in London
09 Nov 2025 Announcement Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
08 Nov 2025 Announcement Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
04 Nov 2025 Announcement Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
04 Nov 2025 Announcement Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
03 Nov 2025 Announcement Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
30 Oct 2025 Announcement Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
30 Oct 2025 CNBC Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
29 Oct 2025 Announcement Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
29 Oct 2025 Announcement European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
28 Oct 2025 Announcement Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
28 Oct 2025 Announcement Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
27 Oct 2025 Announcement U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study
23 Oct 2025 Announcement eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience
23 Oct 2025 Announcement FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer
23 Oct 2025 Announcement Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
21 Oct 2025 Announcement Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
20 Oct 2025 Announcement Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
20 Oct 2025 Announcement KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
19 Oct 2025 Announcement Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
18 Oct 2025 Announcement KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
18 Oct 2025 Announcement KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
18 Oct 2025 Announcement KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
16 Oct 2025 Announcement Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
15 Oct 2025 Announcement Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection
09 Oct 2025 Announcement Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
09 Oct 2025 Announcement Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
07 Oct 2025 Announcement Merck Completes Acquisition of Verona Pharma
06 Oct 2025 Announcement Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
01 Oct 2025 Announcement Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30
30 Sep 2025 Announcement WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
19 Sep 2025 Announcement Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
19 Sep 2025 Announcement Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
19 Sep 2025 Announcement FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
19 Sep 2025 CNBC RFK Jr.'s vaccine panel postpones vote on whether to delay babies' first hepatitis B shot
17 Sep 2025 Announcement Advancing Cancer Research Brings New Hope for Patients Worldwide
15 Sep 2025 Announcement Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab
11 Sep 2025 Announcement CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
07 Sep 2025 Announcement Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Show more
TTM Dividend Yield 1.60%
5Y Average Dividend Yield 2.96%
Payout Ratio 45.93%
Expected Next Dividend Payment Jan 2026
Ex Date Announcement Date Payment Date Details
17 Mar 2025 28 Jan 2025 07 Apr 2025 0.81 Cash
16 Dec 2024 19 Nov 2024 08 Jan 2025 0.81 Cash
16 Sep 2024 23 Jul 2024 07 Oct 2024 0.77 Cash
17 Jun 2024 28 May 2024 08 Jul 2024 0.77 Cash
14 Mar 2024 23 Jan 2024 05 Apr 2024 0.77 Cash
14 Dec 2023 28 Nov 2023 08 Jan 2024 0.77 Cash
14 Sep 2023 25 Jul 2023 06 Oct 2023 0.73 Cash
14 Jun 2023 23 May 2023 10 Jul 2023 0.73 Cash
14 Mar 2023 24 Jan 2023 10 Apr 2023 0.73 Cash
14 Dec 2022 29 Nov 2022 09 Jan 2023 0.73 Cash
14 Sep 2022 26 Jul 2022 07 Oct 2022 0.69 Cash
14 Jun 2022 24 May 2022 08 Jul 2022 0.69 Cash
14 Mar 2022 25 Jan 2022 07 Apr 2022 0.69 Cash
14 Dec 2021 30 Nov 2021 07 Jan 2022 0.69 Cash
14 Sep 2021 27 Jul 2021 07 Oct 2021 0.65 Cash
14 Jun 2021 25 May 2021 07 Jul 2021 0.65 Cash
12 Mar 2021 26 Jan 2021 07 Apr 2021 0.65 Cash
14 Dec 2020 17 Nov 2020 08 Jan 2021 0.65 Cash
14 Sep 2020 28 Jul 2020 07 Oct 2020 0.61 Cash
12 Jun 2020 26 May 2020 07 Jul 2020 0.61 Cash
13 Mar 2020 28 Jan 2020 07 Apr 2020 0.61 Cash
13 Dec 2019 20 Nov 2019 08 Jan 2020 0.61 Cash
13 Sep 2019 24 Jul 2019 07 Oct 2019 0.55 Cash
14 Jun 2019 29 May 2019 08 Jul 2019 0.55 Cash
14 Mar 2019 30 Jan 2019 05 Apr 2019 0.55 Cash
14 Dec 2018 26 Oct 2018 08 Jan 2019 0.55 Cash
14 Sep 2018 25 Jul 2018 05 Oct 2018 0.48 Cash
14 Jun 2018 23 May 2018 09 Jul 2018 0.48 Cash
14 Mar 2018 24 Jan 2018 06 Apr 2018 0.48 Cash
14 Dec 2017 29 Nov 2017 08 Jan 2018 0.48 Cash
14 Sep 2017 26 Jul 2017 06 Oct 2017 0.47 Cash
13 Jun 2017 24 May 2017 10 Jul 2017 0.47 Cash
13 Mar 2017 28 Feb 2017 07 Apr 2017 0.47 Cash
13 Dec 2016 22 Nov 2016 09 Jan 2017 0.47 Cash
13 Sep 2016 26 Jul 2016 07 Oct 2016 0.46 Cash
13 Jun 2016 25 May 2016 08 Jul 2016 0.46 Cash
11 Mar 2016 24 Feb 2016 07 Apr 2016 0.46 Cash
11 Dec 2015 24 Nov 2015 08 Jan 2016 0.46 Cash
11 Sep 2015 22 Jul 2015 07 Oct 2015 0.45 Cash
11 Jun 2015 26 May 2015 08 Jul 2015 0.45 Cash
12 Mar 2015 24 Feb 2015 08 Apr 2015 0.45 Cash
11 Dec 2014 25 Nov 2014 08 Jan 2015 0.45 Cash
11 Sep 2014 23 Jul 2014 07 Oct 2014 0.44 Cash
12 Jun 2014 27 May 2014 08 Jul 2014 0.44 Cash
13 Mar 2014 25 Feb 2014 07 Apr 2014 0.44 Cash
12 Dec 2013 26 Nov 2013 08 Jan 2014 0.44 Cash
12 Sep 2013 23 Jul 2013 07 Oct 2013 0.43 Cash
13 Jun 2013 28 May 2013 08 Jul 2013 0.43 Cash
13 Mar 2013 26 Feb 2013 05 Apr 2013 0.43 Cash
13 Dec 2012 27 Nov 2012 08 Jan 2013 0.43 Cash
13 Sep 2012 24 Jul 2012 05 Oct 2012 0.42 Cash
13 Jun 2012 22 May 2012 09 Jul 2012 0.42 Cash
13 Mar 2012 28 Feb 2012 06 Apr 2012 0.42 Cash
13 Dec 2011 10 Nov 2011 09 Jan 2012 0.42 Cash
13 Sep 2011 26 Jul 2011 07 Oct 2011 0.38 Cash
13 Jun 2011 24 May 2011 08 Jul 2011 0.38 Cash
11 Mar 2011 22 Feb 2011 07 Apr 2011 0.38 Cash
13 Dec 2010 23 Nov 2010 07 Jan 2011 0.38 Cash
13 Sep 2010 27 Jul 2010 07 Oct 2010 0.38 Cash
11 Jun 2010 26 May 2010 08 Jul 2010 0.38 Cash
11 Mar 2010 23 Feb 2010 07 Apr 2010 0.38 Cash
11 Dec 2009 24 Nov 2009 08 Jan 2010 0.38 Cash
02 Sep 2009 28 Jul 2009 01 Oct 2009 0.38 Cash
04 Jun 2009 27 May 2009 01 Jul 2009 0.38 Cash
04 Mar 2009 24 Feb 2009 01 Apr 2009 0.38 Cash
03 Dec 2008 25 Nov 2008 02 Jan 2009 0.38 Cash
03 Sep 2008 22 Jul 2008 01 Oct 2008 0.38 Cash
04 Jun 2008 27 May 2008 01 Jul 2008 0.38 Cash
05 Mar 2008 26 Feb 2008 01 Apr 2008 0.38 Cash
05 Dec 2007 27 Nov 2007 02 Jan 2008 0.38 Cash
05 Sep 2007 24 Jul 2007 01 Oct 2007 0.38 Cash
06 Jun 2007 22 May 2007 02 Jul 2007 0.38 Cash
07 Mar 2007 27 Feb 2007 02 Apr 2007 0.38 Cash
06 Dec 2006 28 Nov 2006 02 Jan 2007 0.38 Cash
30 Aug 2006 25 Jul 2006 02 Oct 2006 0.38 Cash
31 May 2006 23 May 2006 03 Jul 2006 0.38 Cash
31 Aug 2005 26 Jul 2005 03 Oct 2005 0.38 Cash
01 Jun 2005 24 May 2005 01 Jul 2005 0.38 Cash
02 Mar 2005 22 Feb 2005 01 Apr 2005 0.38 Cash
01 Dec 2004 23 Nov 2004 03 Jan 2005 0.38 Cash
01 Sep 2004 27 Jul 2004 01 Oct 2004 0.38 Cash
02 Jun 2004 25 May 2004 01 Jul 2004 0.37 Cash
03 Mar 2004 24 Feb 2004 01 Apr 2004 0.37 Cash
03 Dec 2003 25 Nov 2003 02 Jan 2004 0.37 Cash
03 Sep 2003 22 Jul 2003 01 Oct 2003 0.37 Cash
04 Jun 2003 27 May 2003 01 Jul 2003 0.36 Cash
05 Mar 2003 25 Feb 2003 01 Apr 2003 0.36 Cash
04 Dec 2002 26 Nov 2002 02 Jan 2003 0.36 Cash
04 Sep 2002 23 Jul 2002 01 Oct 2002 0.36 Cash
05 Jun 2002 28 May 2002 01 Jul 2002 0.35 Cash
06 Mar 2002 26 Feb 2002 01 Apr 2002 0.35 Cash
05 Dec 2001 27 Nov 2001 02 Jan 2002 0.35 Cash
30 Aug 2001 24 Jul 2001 01 Oct 2001 0.35 Cash
31 May 2001 22 May 2001 02 Jul 2001 0.34 Cash
07 Mar 2001 27 Feb 2001 02 Apr 2001 0.34 Cash
06 Dec 2000 28 Nov 2000 02 Jan 2001 0.34 Cash
30 Aug 2000 25 Jul 2000 02 Oct 2000 0.34 Cash
31 May 2000 22 May 2000 03 Jul 2000 0.29 Cash
01 Mar 2000 22 Feb 2000 03 Apr 2000 0.29 Cash
01 Dec 1999 23 Nov 1999 03 Jan 2000 0.29 Cash
01 Sep 1999 27 Jul 1999 01 Oct 1999 0.29 Cash
02 Jun 1999 25 May 1999 01 Jul 1999 0.27 Cash
03 Mar 1999 23 Feb 1999 01 Apr 1999 0.27 Cash
02 Dec 1998 24 Nov 1998 04 Jan 1999 0.54 Cash
02 Sep 1998 28 Jul 1998 01 Oct 1998 0.54 Cash
03 Jun 1998 26 May 1998 01 Jul 1998 0.45 Cash
04 Mar 1998 24 Feb 1998 01 Apr 1998 0.45 Cash
03 Dec 1997 25 Nov 1997 02 Jan 1998 0.45 Cash
03 Sep 1997 22 Jul 1997 01 Oct 1997 0.45 Cash
05 Jun 1997 28 May 1997 01 Jul 1997 0.42 Cash
05 Mar 1997 25 Feb 1997 01 Apr 1997 0.42 Cash
05 Dec 1996 26 Nov 1996 02 Jan 1997 0.4 Cash
04 Sep 1996 23 Jul 1996 01 Oct 1996 0.4 Cash
06 Jun 1996 29 May 1996 01 Jul 1996 0.34 Cash
06 Mar 1996 27 Feb 1996 01 Apr 1996 0.34 Cash
06 Dec 1995 28 Nov 1995 02 Jan 1996 0.34 Cash
05 Sep 1995 25 Jul 1995 02 Oct 1995 0.34 Cash
02 Jun 1995 23 May 1995 03 Jul 1995 0.3 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.62 2 1.60
2024 3.08 4 3.10
2023 2.92 4 2.68
2022 2.76 4 2.49
2021 2.60 4 3.39
2020 2.44 4 3.13
2019 2.20 4 2.54
2018 1.92 4 2.63
2017 1.88 4 3.50
2016 1.84 4 3.28
2015 1.80 4 3.57
2014 1.76 4 3.25
2013 1.72 4 3.60
2012 1.68 4 4.30
2011 1.52 4 4.23
2010 1.52 4 4.42
2009 1.52 4 4.36
2008 1.52 4 5.24
2007 1.52 4 2.74
2006 0.760 2 1.83
2005 1.52 4 5.01
2004 1.49 4 4.86
2003 1.45 4 3.29
2002 1.41 4 2.61
2001 1.37 4 2.44
2000 1.21 4 1.35
1999 1.37 4 2.14
1998 1.89 4 2.69
1997 1.69 4 3.34
1996 1.42 4 3.74
1995 0.640 2 2.04
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria